- 07:00 AM Indian IT firms eye continental Europe for growth
- 07:00 AM PM Singh says assured by US. on Pakistan
- 07:00 AM Gold at record as dollar drops
- 07:00 AM US consumer, labour data buoy optimism on recovery
- 11:24 PM Student visa applications to US, UK see 25% drop
- 10:46 PM Astec LifeSciences to start a project in Q3FY11
- 10:20 PM Rangebound session for Nifty ahead of Nov series e...
- 09:30 PM Politics stirs over Ayodhya mosque report
- 09:23 PM Clean energy, better homes cut pollution, save liv...
- 09:11 PM US to face stimulus aftershocks: Warren Buffett



New Delhi, Feb. 7
Ranbaxy Laboratories Ltd has received US Food and Drug Administration approval to make and sell the generic version of GlaxoSmithKline’s anti-infective Ceftin, which will be the first generic formulation in the market.
According to the company, the Office of Generic Drugs, USFDA has determined the two strengths of Ranbaxy’s formulations of Cefuroxime Axetil for Oral Suspension USP, or generic Ceftin to be bioequivalent and have the same therapeutic effect as that of GSK’s drug. Total annual market sales for Cefuroxime Axetil suspension were $28.7 million.
The drug is meant for the treatment of paediatric patients between three months and 12 years with mild to moderate bacterial infections such as pharyngitis or tonsillitis, acute bacterial otitis media and impetigo.
“Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to be the only generic company to offer both dosage forms for a product that is highly prescribed.
We will offer the Cefuroxime as liquid intended primarily for children that will ease in the administration of this anti-infective. This product will further expand our product portfolio of affordable generic alternatives and will be launched immediately to all classes of trade,” said Mr Jim Meehan, Vice-President, Sales and Distribution for RPI, US, in a release.
Taken from Business Line
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- US to face stimulus aftershocks: Warren Buffett

- Expert stock/sector picks in these markets

- India to sell $70 bn shares in 3 years: Morgan Stanley
- Mkts to remain strong; bet on midcaps: Ramesh Damani
- Nifty to test 5500 post 5-7% correction: JM Financial

- Satyam says no out-of-court settlement with creditors
- Student visa applications to US, UK see 25% drop
- Sell Mahindra Satyam: Sandeep Wagle

- S&P raises fears over health of some banks
Source: ft.com
- Auto sector growth to push up demand for rubber
Source: Business Line
- High networth individuals see glitter in commodities
Source: Business Line
- Tatas may launch electric Indica by early 2011
Source: Business Line










